Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develop… Read more
Orchestra BioMed Holdings Inc. (OBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.333x
Based on the latest financial reports, Orchestra BioMed Holdings Inc. (OBIO) has a cash flow conversion efficiency ratio of -0.333x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.55 Million) by net assets ($43.74 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Orchestra BioMed Holdings Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Orchestra BioMed Holdings Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Orchestra BioMed Holdings Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Orchestra BioMed Holdings Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jinfa Labi Maternity & Baby Articles Co Ltd
SHE:002762
|
-0.014x |
|
PT Ancara Logistics Indonesia
JK:ALII
|
0.016x |
|
DAE-IL Corporation
KO:092200
|
-0.032x |
|
Premier Miton Group plc
PINK:PASMF
|
0.045x |
|
Bakkt Holdings Inc
NYSE:BKKT
|
-0.363x |
|
Valid Soluções S.A
SA:VLID3
|
0.074x |
|
Pan German Universal Motors Ltd.
TW:2247
|
0.021x |
|
GAEC Educacao SA
SA:ANIM3
|
0.141x |
Annual Cash Flow Conversion Efficiency for Orchestra BioMed Holdings Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Orchestra BioMed Holdings Inc. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $32.96 Million | $-50.56 Million | -1.534x | -126.29% |
| 2023-12-31 | $68.04 Million | $-46.13 Million | -0.678x | -21.59% |
| 2022-12-31 | $52.53 Million | $-29.29 Million | -0.558x | -304.40% |
| 2021-12-31 | $-71.23 Million | $-19.43 Million | 0.273x | -49.43% |
| 2020-12-31 | $-48.54 Million | $-26.18 Million | 0.539x | -- |